Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

  • End date
    Nov 23, 2023
  • participants needed
  • sponsor
Updated on 4 October 2022


This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.

Condition Pruritus
Treatment Placebo, Linerixibat
Clinical Study IdentifierNCT04950127
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Male and female participants must be between 18 to 80 years of age inclusive, at the time of signing the informed consent
Participants who have documented PBC
Participants who have moderate to severe itch

Exclusion Criteria

Symptoms suggestive of active coronavirus disease 2019 (COVID-19) infection whilst symptoms persist or known COVID-19 positive contacts within the past 14 days should be excluded for at least 14 days from the exposure
Total bilirubin >2.0 times Upper Limit of Normal (ULN) using the average of two Baseline measures
Screening Alanine Aminotransferase (ALT) > 6 times ULN in a single Baseline measure or ALT > 5 times ULN using the average of two Baseline measures
Screening estimated glomerular filtration rate (eGFR) <30 milliliter per minute per 1.73 square meter (mL/min/1.73m^2)
History or presence of hepatic decompensation (e.g., variceal bleeding, hepatic encephalopathy or ascites)
Presence of actively replicating viral hepatitis B or C (HBV, HCV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease and/or confirmed hepatocellular carcinoma or biliary cancer
Current clinically significant diarrhea or active inflammatory ileal disease according to Investigator´s clinical judgment
Current symptomatic cholelithiasis or cholecystitis
Current diagnosis of primary skin disorders with itch symptoms (e.g., atopic dermatitis, psoriasis)
Primary sleep disorders such as but are not limited to sleep apnea, narcolepsy, hypersomnia
Current/previous diagnosis of colorectal cancer
Initiation, discontinuation or change in dose of ursodeoxycholic acid (UDCA), bezafibrate or fenofibrate in the 8 weeks prior to Screening
Use of obeticholic acid: within 8 weeks prior to Screening. (Participants may not initiate or restart during the study)
Initiation, discontinuation, or change in dose of any of the following in the 8 weeks prior to Screening: bile acid binding resins, rifampicin, naltrexone, naloxone, nalfurafine, pregabalin, gabapentin, sertraline or other selective serotonin reuptake inhibitor (SSRIs), antihistamines used for the treatment of itching
Administration of any other human ileal bile acid transporter (IBAT) inhibitor in the 12 weeks prior to screening
Any planned procedures intended to treat cholestatic pruritus such as nasobiliary drainage or ultraviolet light therapy from Screening and throughout the study
History of sensitivity or intolerance to the study treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note